| Institution | Maastricht University, The Netherlands |
| Contacts | [email protected] |
Angela Brand, MD PhD MPH (USA) is Founding Director and Full Professor of the Institute for Public Health Genomics (IPHG) at the Faculty of Health, Medicine and Life Sciences at Maastricht University, the Netherlands, as well as Dr. T.M.Pai Endowed Chair on Public Health Genomics at Manipal University, India. Before she worked in the clinics, at various academic institutions and in governmental bodies in the USA and Germany.
She is Paediatrician, Specialist in Public Health Medicine, holds a PhD in pathology (Münster University, Germany) and a Master of Public Health (MPH) from Johns Hopkins University, USA. She received her habilitation in Public Health Genomics focusing on Health Technology Assessment (Bremen University, Germany) being in Europe the first HTA on genomics. She has been the pioneer of Public Health Genomics in Europe and established successfully this field in more than 15 European Member States within the last years.
She is Fellow of the Rockefeller Foundation, USA, and of the 21st Century Trust of the Wellcome Trust, UK. She was Coordinator of the Public Health Genomics European Network (PHGEN, www.phgen.eu) and Full Partner and Steering Committee Member of the EU Flagship Pilot Project IT Future of Medicine (ITFoM).
Currently she is Director of the European Centre for Public Health Genomics (ECPHG), Coordinator of the FP7 project ERAfrica/innXchange at United Nations University (UNU-MERIT) of Maastricht University, Full Partner of the FP7 CSA PerMed on Personalised Healthcare and the FP7 project RARE-Bestpractises on rare diseases, WG4 leader of the COST Action EU-Pancreas, Founding President of the Section Public Health Genomics within the European Public Health Association (EUPHA), Editor-in-Chief of the international journal Public Health Genomics, Advisory Board Member of the EU Innovation Medicine Initiative (IMI) project OncoTrack, of ALACRiS Theranostics GmbH (Germany), and of the Ludwig Boltzmann Institute for Health Technology Assessment (LBI), Steering Committee Member of the "Forward Look on Personalized Medicine" of the European Science Foundation, of the Genomic Medicine Alliance (GMA) and of the European Alliance for Personalised Medicine (EAPM).
She serves as Expert for the European Agency for Reconstruction, the OECD, WHO, the EC, the ECDC, the Netherlands Genomics Initiative (NGI), the German Robert Koch-Institut (RKI), Genome Canada, the European Science Foundation, AXA Research Fund among others. She collaborates with Roche, Pfizer, AMGEN, Novartis, MSD, Bayer HealthCare etc. and produced for them also HTA reports.
Work Group: